title: Aliskiren/amlodipine combination for the treatment of hypertension.
abstract: The challenge of managing hypertension is exemplified by the limited success of monotherapy and necessity for multiple drug regimens targeting complimentary pathways. Recent evidence suggests that combination therapy including angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs) provides blood pressure control while reducing cardiovascular mortality and morbidity over ACE inhibitor/diuretic therapy. However, CCBs, ACE inhibitors and angiotensin receptor blockers all increase plasma renin activity (PRA), promoting angiotensin I accumulation and angiotensin II production through alternative pathways. While the clinical ramifications of this and other compensatory pathways activating the renin-angiotensin-aldosterone system are unclear, the recently approved aliskiren/amlodipine antihypertensive combination pill has been shown to decrease PRA via aliskiren's direct inhibition of renin. The purpose of this monograph is to review the mechanisms of action, pharmacodynamics, and safety and efficacy profile of the aliskiren/amlodipine combination pill.
authors.affiliation: William Beaumont Hospital, Ministrelli Women's Heart Center, Royal Oak, Michigan 48073, USA. Scott.Billecke@beaumont.edu
authors.forename: Scott S
authors.initials: SS
authors.lastname: Billecke
authors.forename: P A
authors.initials: PA
authors.lastname: Marcovitz
mesh_terms: D000577:Amides / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D017311:Amlodipine / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004347:Drug Interactions; D005650:Fumarates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D017311:Amlodipine; D000959:Antihypertensive Agents; D004338:Drug Combinations; D005650:Fumarates; D000092502:Renin Inhibitors; C446481:aliskiren